ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients

Disclosures: D.S. received honoraria or performed consulting for Janssen, Sanofi and Takeda. N.S. received honoraria from Roche, Celgene, CTI Life Sciences, Riemser, Janssen and performed consulting for Roche, Janssen, CTI Life Sciences, Riemser, Janssen Oncology. A.L.F. performed consulting for Infinity Pharmaceuticals and is inventor of technology for which Mayo Clinic holds an unlicensed patent or has submitted a patent application. D.D.W. received honoraria or performed consulting for Seattle Genetics. A.R. performed consulting for Roche, Celgene, Morphosys. M.J.M. received Research Funding from Celgene. J.O.A. has Leadership in TESARO and performed consulting for ZIOPHARM Oncology, Conatus IDMC. J.M.V. performed consulting for Bio Connections and received Research Funding from Celgene, Genentech, Incyte, Janssen Biotech, Acerta Pharma, Kite Pharma, Seattle Genetics, Novartis, Amgen, Bristol-Myers Squibb, Allos Therapeutics. K.J.S. received honoraria from Seattle Genetics, Bristol-Myers Squibb, Merck, Novartis, Gilead Sciences, Abbvie, Takeda and performed consulting for Seattle Genetics, Bristol-Myers Squibb, Merck, Servier, Novartis, Gilead Sciences, and received Research Funding from Roche. The remaining authors declare no competing financial interests.

Contributions: D.S., K.J.S., D-P.N., and J-P.J. designed the study, analyzed results, and wrote the manuscript; D-P.N. and J-P.J. performed statistical analyses; All authors collected and interpreted data; All authors approved the manuscript.